



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

de la MONTE *et al.*

Appl. No. 09/380,203

§ 102(e) Date: April 25, 2000

For: **Transgenic Animals and Cell
Lines for Screening Drugs
Effective for the Treatment or
Prevention of Alzheimer's Disease**

Confirmation No.: 2325

Art Unit: 1635

Examiner: Whiteman, B.

Atty. Docket: 0609.4370001/RWE/FRC

#29/K.T.
1/28
E

Amendment And Reply Under 37 C.F.R. § 1.111

RECEIVED

JAN 24 2003

TECH-CENTER 1600/2

Commissioner for Patents
Washington, D.C. 20231

Sir:

In reply to the Office Action dated **October 21, 2002**, (PTO Prosecution File Wrapper Paper No. 28), Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.121 and MPEP 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of